Author's response to reviews

Title: Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?

Authors:

William P. Hausdorff (william.hausdorff@gskbio.com)
Bernard Hoet (bernard.hoet@gskbio.com)
Lode Schuerman (lode.schuerman@gskbio.com)

Version: 2 Date: 23 June 2009

Author's response to reviews:

23 June 2009

Dear Doctor Norton,

Please find enclosed the manuscript entitled “Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?” which we re-submit for consideration for publication as a “debate” piece in the BMC Pediatric journal.

The main changes that have been made are described below:

1. Based on the QUOROM paper, the methods section has been expended to more fully describe the search strategy. In addition, more details have been provided in Table 1 regarding precise endpoints assessed (and in the process removed some extraneous dates).

2. I included an additional, very recent example from Quebec of a 19A effectiveness calculation based on the ESPID abstracts to Table 1. The reference for that additional example needs to be inserted in the reference list.

3. I have retitled the Tables, with small changes to their legends.

Also, to facilitate coordination of the development of the manuscript, would it be possible to put Valentine Wascotte, publications manager (valentine.wascotte@gskbio.com) in cc of the exchanges of e-mails related to this publication?

Thank you for considering our manuscript for publication.

Yours sincerely,

William Hausdorff, PhD
Director, Epidemiology & Scientific Strategy
Paediatric Vaccines
GlaxoSmithKline Biologicals